Multiple Assemblies exist for SMTL entry 5vp1
Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4-(trifluoromethoxy)phenyl]-2-methoxyethyl}-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders; X-RAY DIFFRACTION 1.86 Å

	SMTL ID 5vp1.1 Ligands ZINC ION; MAGNESIUM ION; N-{(1S)-2-hydroxy-2-methyl-1-[4-(trifluoromethoxy)phenyl]propyl}-6-methyl-5-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Polypeptides cGMP-dependent 3',5'-cyclic phosphodiesterase Oligo-state homo-dimer
	SMTL ID 5vp1.2 Ligands ZINC ION; MAGNESIUM ION; N-{(1S)-2-hydroxy-2-methyl-1-[4-(trifluoromethoxy)phenyl]propyl}-6-methyl-5-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Polypeptides cGMP-dependent 3',5'-cyclic phosphodiesterase Oligo-state homo-dimer